Close Menu

NEW YORK – Fluidigm said on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.

Fluidigm's stock soared on the announcement. In early Wednesday trading on the Nasdaq, shares of the company were up around 29 percent at $11.34.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.